{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:29:25Z","timestamp":1790738965916,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) have revolutionized the treatment of heart failure and are now established as disease-modifying therapies across the spectrum of left ventricular ejection fraction. More recently, these agents have been evaluated in the early post-acute myocardial infarction (AMI) setting, raising interest in their potential role beyond heart failure prevention. Evidence from post-AMI randomized trials and contemporary meta-analyses consistently shows neutral effects on ischemic coronary outcomes, despite favorable effects on heart failure-related endpoints, ventricular remodeling, and cardiometabolic parameters. At the same time, data from experimental and translational research provide a biological framework in which SGLT2i exert anti-atherogenic effects through multiple complementary mechanisms, including improvement of cardiometabolic risk factors, attenuation of vascular and systemic inflammation, modulation of endothelial function, regulation of vascular smooth muscle cell behavior, macrophage inflammatory polarization, inhibition of inflammasome signaling, and modulation of the perivascular adipose tissue\u2013vascular interface. Taken together, the available evidence highlights a dissociation between clinical trial outcomes in the early post-AMI phase and the underlying vascular biology associated with SGLT2 inhibition. While the dominant early clinical effects of SGLT2i appear to relate to hemodynamic and heart failure-preventive mechanisms, their potential impact on atherosclerotic disease may be more gradual and context-dependent. This review summarizes current clinical and mechanistic evidence supporting this interpretation and discusses the implications for understanding the role of SGLT2i in patients after AMI.<\/jats:p>","DOI":"10.3390\/jcm15062260","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:21:16Z","timestamp":1773674476000},"page":"2260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge"],"prefix":"10.3390","volume":"15","author":[{"given":"Angela","family":"Buonpane","sequence":"first","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"},{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ciardetti","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale San Cataldo, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9165-7732","authenticated-orcid":false,"given":"Giancarlo","family":"Trimarchi","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"},{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarla","family":"Scalone","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Alessandro","family":"Coceani","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale San Cataldo, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Emilio","family":"Pastormerlo","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marchi","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-4732","authenticated-orcid":false,"given":"Umberto","family":"Paradossi","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Berti","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-4753","authenticated-orcid":false,"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Ranieri","family":"De Caterina","sequence":"additional","affiliation":[{"name":"Fondazione Toscana G. Monasterio, Ospedale del Cuore \u201cG. Pasquinucci\u201d, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15537\/smj.2022.43.5.20220018","article-title":"Effect of a Low Dose of Empagliflozin on Short-Term Outcomes in Type 2 Diabetics with Acute Coronary Syndrome after Percutaneous Coronary Intervention","volume":"43","author":"Adel","year":"2022","journal-title":"SMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of Empagliflozin versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: The EMBODY Trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in Acute Myocardial Infarction: The EMMY Trial","volume":"43","author":"Kolesnik","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2023.03.002","article-title":"Impact of Dapagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients\u2014DACAMI (a Randomized Controlled Clinical Trial)","volume":"379","author":"Dayem","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40256-024-00662-4","article-title":"Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial","volume":"24","author":"Khani","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after Acute Myocardial Infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rroji, M., Spahia, N., Figurek, A., and Spasovski, G. (2025). Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030728"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xu, J., Hirai, T., Koya, D., and Kitada, M. (2021). Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010137"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why Do SGLT2 Inhibitors Reduce Heart Failure Hospitalization? A Differential Volume Regulation Hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00228-025-03830-w","article-title":"Effects of Oral Antidiabetic Agents on the Renin\u2013Angiotensin\u2013Aldosterone System","volume":"81","author":"Yang","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The Failing Heart\u2014An Engine Out of Fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/dom.12881","article-title":"Determinants of the Increase in Ketone Concentration during SGLT2 Inhibition in NGT, IFG and T2DM Patients","volume":"19","author":"Daniele","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin Increases Cardiac Energy Production in Diabetes","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","article-title":"The Role of Inflammation and Cell Death in the Pathogenesis, Progression and Treatment of Heart Failure","volume":"21","author":"Briasoulis","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/HYPERTENSIONAHA.116.07307","article-title":"Inflammation in Heart Failure: The Holy Grail?","volume":"68","author":"Mehta","year":"2016","journal-title":"Hypertension"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"133281","DOI":"10.1016\/j.ijcard.2025.133281","article-title":"Inflammation in Chronic Heart Failure: An Unsolved Puzzle","volume":"432","author":"Trimarchi","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Iannantuoni, F., de Mara\u00f1on, A.M., Diaz-Morales, N., Falcon, R., Ba\u00f1uls, C., Abad-Jimenez, Z., Victor, V.M., Hernandez-Mijares, A., and Rovira-Llopis, S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111814"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin Reduces Inflammation and Fibrosis Biomarkers: A Potential Mechanism of Action for Beneficial Effects of SGLT2 Inhibitors in Diabetic Kidney Disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 Inhibitor Dapagliflozin Attenuates the Activity of ROS-NLRP3 Inflammasome Axis in Steatohepatitis with Diabetes Mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cardfail.2015.04.014","article-title":"The Importance of NLRP3 Inflammasome in Heart Failure","volume":"21","author":"Butts","year":"2015","journal-title":"J. Card. Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The Ketone Metabolite \u03b2-Hydroxybutyrate Blocks NLRP3 Inflammasome\u2013Mediated Inflammatory Disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial Dysfunction in Pathophysiology of Heart Failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 Inhibition with Empagliflozin Attenuates Myocardial Oxidative Stress and Fibrosis in Diabetic Mice Heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14796678.2025.2464449","article-title":"The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Clinical Outcomes after Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"21","author":"Khan","year":"2025","journal-title":"Future Cardiol."},{"key":"ref_41","first-page":"17122","article-title":"Early Use of SGLT2 Inhibitors after Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"135","author":"Kurek","year":"2025","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1002\/edm2.514","article-title":"Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomised Controlled Trials","volume":"7","author":"Ahmed","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.12997\/jla.2025.14.3.326","article-title":"Administration of Sodium-Glucose Cotransporter-2 Inhibitors Following Acute Myocardial Infarction: A Systematic Review, Meta-Analysis, and Meta-Regression of Randomized Trials","volume":"14","author":"Hariyanto","year":"2025","journal-title":"J. Lipid Atheroscler."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-024-02540-4","article-title":"Impact of Sodium\u2013glucose Cotransporter-2 Inhibitors in Patients with Recent versus Previous Myocardial Infarction: A Systematic Review and Meta-Analysis","volume":"24","author":"Scardini","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.clinthera.2024.06.010","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Acute Coronary Syndrome: A Modern Cinderella?","volume":"46","author":"Karakasis","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"120424","DOI":"10.1016\/j.atherosclerosis.2025.120424","article-title":"Unlocking the Secrets: Adipose Tissue Dysfunction and Atherosclerosis-Mechanisms and Innovative Therapeutic Approaches","volume":"408","author":"Matar","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107255","DOI":"10.1016\/j.vph.2023.107255","article-title":"Inflammation and the Pathogenesis of Atherosclerosis","volume":"154","author":"Libby","year":"2024","journal-title":"Vasc. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6305735","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE\u2212\/\u2212 Mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.02.028","article-title":"SGLT2 Inhibition Reduces Atherosclerosis by Enhancing Lipoprotein Clearance in Ldlr\u2212\/\u2212 Type 1 Diabetic Mice","volume":"271","author":"Murphy","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The Beneficial Effects of Empagliflozin, an SGLT2 Inhibitor, on Atherosclerosis in ApoE\u2212\/\u2212 Mice Fed a Western Diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-Induced Upregulation of SGLT1 and 2 Contributes to Human Microparticle-stimulated Endothelial Senescence and Dysfunction: Protective Effect of Gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","article-title":"Hyperglycaemic Impairment of PAR2-Mediated Vasodilation: Prevention by Inhibition of Aortic Endothelial Sodium-Glucose-Co-Transporter-2 and Minimizing Oxidative Stress","volume":"109","author":"Saifeddine","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute Canagliflozin Treatment Protects against in Vivo Myocardial Ischemia\u2013Reperfusion Injury in Non-Diabetic Male Rats and Enhances Endothelium-Dependent Vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic Control by the SGLT2 Inhibitor Empagliflozin Decreases Aortic Stiffness, Renal Resistivity Index and Kidney Injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor \u03b1-Stimulated Human Coronary Arterial Endothelial Cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2012.07.064","article-title":"Pathogenesis of Acute Coronary Syndromes","volume":"61","author":"Crea","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"109825","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 Inhibitor Empagliflozin Attenuates Interleukin-17A-Induced Human Aortic Smooth Muscle Cell Proliferation and Migration by Targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-Dependent IL-1\u03b2 and IL-18 Secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell. Signal."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Terasaki, M., Hiromura, M., Mori, Y., Kohashi, K., Nagashima, M., Kushima, H., Watanabe, T., and Hirano, T. (2015). Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143396"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Feij\u00f3o-Band\u00edn, S., Arag\u00f3n-Herrera, A., Otero-Santiago, M., Anido-Varela, L., Mora\u00f1a-Fern\u00e1ndez, S., Taraz\u00f3n, E., Rosell\u00f3-Llet\u00ed, E., Portol\u00e9s, M., Gualillo, O., and Gonz\u00e1lez-Juanatey, J.R. (2022). Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105634"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 Inflammasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cmet.2012.02.011","article-title":"Autophagy Links Inflammasomes to Atherosclerotic Progression","volume":"15","author":"Razani","year":"2012","journal-title":"Cell Metab."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cai, M., Zhao, D., Han, X., Han, S., Zhang, W., Zang, Z., Gai, C., Rong, R., and Gao, T. (2023). The Role of Perivascular Adipose Tissue-Secreted Adipocytokines in Cardiovascular Disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1271051"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jcmg.2023.08.021","article-title":"Noninvasive Coronary Atherosclerotic Plaque Imaging","volume":"16","author":"Kwiecinski","year":"2023","journal-title":"JACC. Cardiovasc. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular Adipose Tissue as a Source of Therapeutic Targets and Clinical Biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tcm.2024.06.003","article-title":"Enhancing Cardiovascular Risk Stratification: Radiomics of Coronary Plaque and Perivascular Adipose Tissue\u2014Current Insights and Future Perspectives","volume":"35","author":"Corti","year":"2025","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Trimarchi, G., Carerj, M.L., Zito, C., Bella, G.D., Taverna, G., Cusm\u00e0 Piccione, M., Crea, P., Lo Giudice, S., Buonpane, A., and Bonanni, M. (2025). Epicardial Adipose Tissue: A Multimodal Imaging Diagnostic Perspective. Medicina, 61.","DOI":"10.3390\/medicina61060961"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.2459\/JCM.0000000000001433","article-title":"Computed Tomography and Nuclear Medicine for the Assessment of Coronary Inflammation: Clinical Applications and Perspectives","volume":"24","author":"Guaricci","year":"2023","journal-title":"J. Cardiovasc. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(18)31114-0","article-title":"Non-Invasive Detection of Coronary Inflammation Using Computed Tomography and Prediction of Residual Cardiovascular Risk (the CRISP CT Study): A Post-Hoc Analysis of Prospective Outcome Data","volume":"392","author":"Oikonomou","year":"2018","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kim, J.N., Gomez-Perez, L., Zimin, V.N., Makhlouf, M.H.E., Al-Kindi, S., Wilson, D.L., and Lee, J. (2023). Pericoronary Adipose Tissue Radiomics from Coronary Computed Tomography Angiography Identifies Vulnerable Plaques. Bioengineering, 10.","DOI":"10.1101\/2023.01.09.23284346"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"E014959","DOI":"10.1161\/CIRCIMAGING.122.014959","article-title":"Coronary Inflammation and Plaque Vulnerability: A Coronary Computed Tomography and Optical Coherence Tomography Study","volume":"16","author":"Yuki","year":"2023","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","article-title":"Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure with Reduced Ejection Fraction with or Without Diabetes","volume":"4","author":"Yurista","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Buonpane, A., Trimarchi, G., Di Muro, F.M., Nardi, G., Ciardetti, M., Coceani, M.A., Pastormerlo, L.E., Paradossi, U., Berti, S., and Trani, C. (2025). From Vision to Illumination: The Promethean Journey of Optical Coherence Tomography in Cardiology. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155451"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:24:48Z","timestamp":1773674688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15062260"],"URL":"https:\/\/doi.org\/10.3390\/jcm15062260","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}